Publications by Torbjörn Gräslund
Refereegranskade
Artiklar
[1]
J. $$$Zhang et al., "Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.," Journal of Controlled Release, vol. 370, pp. 468-478, 2024.
[2]
S. Pinto et al., "Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide," Journal of Controlled Release, vol. 366, pp. 621-636, 2024.
[3]
S. M. Deyev et al., "Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion," International Journal of Molecular Sciences, vol. 25, no. 8, 2024.
[4]
W. Yin et al., "Comparison of HER2-targeted affibody conjugates loaded with auristatin-and maytansine-derived drugs," Journal of Controlled Release, vol. 355, pp. 515-527, 2023.
[5]
M. Larkina et al., "Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer," International Journal of Molecular Sciences, vol. 23, no. 21, pp. 13443, 2022.
[6]
T. Xu et al., "Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2," Pharmaceutics, vol. 14, no. 3, pp. 522, 2022.
[7]
J. Garousi et al., "Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts : Efficacy and Selection of Companion Imaging Counterpart," Pharmaceutics, vol. 14, no. 8, 2022.
[8]
M. Malm et al., "Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins," Metabolic engineering, vol. 72, pp. 171-187, 2022.
[9]
M. Bronge et al., "Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis," Science Advances, vol. 8, no. 17, 2022.
[10]
Y. Liu et al., "Preclinical Evaluation of a New Format of Ga-68- and In-111-Labeled Affibody Molecule Z(IGF-1R:4551) for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT," Pharmaceutics, vol. 14, no. 7, 2022.
[11]
B. Ladd et al., "Proof-of-Concept of Continuous Transfection for Adeno-Associated Virus Production in Microcarrier-Based Culture," Processes, vol. 10, no. 3, 2022.
[12]
S. S. Rinne et al., "Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules," Biomedicines, vol. 10, no. 6, 2022.
[13]
H. Ding et al., "Affibody-Derived Drug Conjugates Targeting HER2 : Effect of Drug Load on Cytotoxicity and Biodistribution," Pharmaceutics, vol. 13, no. 3, 2021.
[14]
T. Xu et al., "Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model," Cancers, vol. 13, no. 1, 2021.
[15]
T. Xu et al., "Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model," Cancers, vol. 13, no. 16, 2021.
[16]
S. M. Deyev et al., "Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1," Cancers, vol. 13, no. 14, 2021.
[17]
J. Garousi et al., "Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein," Pharmaceutics, vol. 13, no. 11, pp. 1847, 2021.
[18]
W. Yin et al., "The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy," Pharmaceutics, vol. 13, no. 11, pp. 1974-1974, 2021.
[19]
S. M. Deyev et al., "Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1," International Journal of Biological Macromolecules, vol. 145, pp. 216-225, 2020.
[20]
H. Ding et al., "HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions : Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution," Pharmaceutics, vol. 12, no. 4, 2020.
[21]
S. Yu et al., "An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation," PLOS ONE, vol. 14, no. 5, 2019.
[22]
H. Ding et al., "Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates," Cancers, vol. 11, no. 8, 2019.
[23]
H. Liu et al., "Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A," International Journal of Oncology, vol. 55, no. 1, pp. 309-319, 2019.
[24]
M. Altai et al., "Affibody-derived drug conjugates : Potent cytotoxic molecules for treatment of HER2 over-expressing tumors," Journal of Controlled Release, vol. 288, pp. 84-95, 2018.
[25]
J. Seijsing et al., "In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor," Scientific Reports, vol. 8, 2018.
[26]
S. Ståhl et al., "Affibody Molecules in Biotechnological and Medical Applications," Trends in Biotechnology, vol. 35, no. 8, pp. 691-712, 2017.
[27]
T. Gräslund, "Affibody molecules : therapy and in vivo diagnostic applications," New Biotechnology, vol. 33, pp. S48-S48, 2016.
[28]
G. Gunaydin et al., "Fusion of the mouse IgG1 Fc domain to the VHH fragment (ARP1) enhances protection in a mouse model of rotavirus," Scientific Reports, vol. 6, 2016.
[29]
M. Altai et al., "Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin," International Journal of Oncology, vol. 49, no. 3, pp. 1185-1194, 2016.
[30]
A. Alkharusi et al., "Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in glioblastoma multiforme," Oncotarget, vol. 7, no. 48, pp. 79558-79569, 2016.
[31]
B. Mitran et al., "Evaluation of Tc-99m-Z(IGF1R:4551)-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression," Amino Acids, vol. 47, no. 2, pp. 303-315, 2015.
[32]
H. Liu et al., "Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin Z(HER2:2891)-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain," International Journal of Oncology, vol. 47, no. 2, pp. 601-609, 2015.
[33]
J. Seijsing et al., "An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein," Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 48, pp. 17110-17115, 2014.
[34]
S. Shibasaki et al., "Inhibitory effects of H-Ras/Raf-1–binding affibody molecules on synovial cell function," AMB Express, vol. 4, no. 82, 2014.
[35]
C. Hofström et al., "HAHAHA, HEHEHE, HIHIHI, or HKHKHK : Influence of Position and Composition of Histidine Containing Tags on Biodistribution of [Tc-99m(CO)(3)](+)-Labeled Affibody Molecules," Journal of Medicinal Chemistry, vol. 56, no. 12, pp. 4966-4974, 2013.
[36]
J. Seijsing et al., "Robust Expression of the Human Neonatal Fc Receptor in a Truncated Soluble Form and as a Full-Length Membrane-Bound Protein in Fusion with eGFP," PLOS ONE, vol. 8, no. 11, pp. e81350, 2013.
[37]
L. M. Orre et al., "S100A4 interacts with p53 in the nucleus and promotes p53 degradation," Oncogene, vol. 32, no. 49, pp. 5531-5540, 2013.
[38]
H. Lindberg et al., "Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for Tc-99m-labelling at the C terminus," Tumor Biology, vol. 33, no. 3, pp. 641-651, 2012.
[39]
V. Tolmachev et al., "Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule (111)In-DOTA-Z(IGF1R:4551)," Journal of Nuclear Medicine, vol. 53, no. 1, pp. 90-97, 2012.
[40]
K. Larsson et al., "Novel antigen design for the generation of antibodies to G-protein-coupled receptors," JIM - Journal of Immunological Methods, vol. 370, no. 1-2, pp. 14-23, 2011.
[41]
C. Hofström et al., "Use of a HEHEHE Purification Tag Instead of a Hexahistidine Tag Improves Biodistribution of Affibody Molecules Site-Specifically Labeled with Tc-99m, In-111 and I-125," Journal of Medicinal Chemistry, vol. 54, no. 11, pp. 3817-3826, 2011.
[42]
V. Tolmachev et al., "HEHEHE-Tagged Affibody Molecule May Be Purified by IMAC, Is Conveniently Labeled with [Tc-99m(CO)(3)](+), and Shows Improved Biodistribution with Reduced Hepatic Radioactivity Accumulation," Bioconjugate chemistry, vol. 21, no. 11, pp. 2013-2022, 2010.
[43]
S. Grimm et al., "Selection and characterisation of affibody molecules inhibiting the interaction between Ras and Raf in vitro," NEW BIOTECHNOL, vol. 27, no. 6, pp. 766-773, 2010.
[44]
J. Li et al., "Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor," Biotechnology and applied biochemistry, vol. 55, pp. 99-109, 2010.
[45]
E. Vernet et al., "Affibody-mediated retention of the epidermal growth factor receptor in the secretory compartments leads to inhibition of phosphorylation in the kinase domain," New biotechnology, vol. 25, no. 6, pp. 417-423, 2009.
[46]
E. Lundberg, H. Brismar and T. Gräslund, "Selection and characterization of Affibody (R) ligands to the transcription factor c-Jun," Biotechnology and applied biochemistry, vol. 52, pp. 17-27, 2009.
[47]
E. Vernet et al., "Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule," Journal of immunological methods, vol. 338, pp. 1-6, 2008.
[48]
E. Lundberg et al., "A novel method for reproducible fluorescent labeling of small amounts of antibodies on solid phase," JIM - Journal of Immunological Methods, vol. 322, no. 1-2, pp. 40-49, 2007.
[49]
R. M. Gordley et al., "Evolution of programmable zinc finger-recombinases with activity in human cells," Journal of Molecular Biology, vol. 367, no. 3, pp. 802-813, 2007.
[50]
E. Lundberg et al., "Site-specifically conjugated anti-HER2 Affibody® molecules as one-step reagents for target expression analyses on cells and xenograft samples," JIM - Journal of Immunological Methods, vol. 319, no. 1-2, pp. 53-63, 2007.
[51]
M. Hedhammar et al., "Single-step recovery and solid-phase refolding of inclusion body proteins using a polycationic purification tag," Biotechnology Journal, vol. 1, pp. 187-196, 2006.
[52]
T. Gräslund et al., "Exploring strategies for the design of artificial transcription factors," Journal of Biological Chemistry, vol. 280, no. 5, pp. 3707-3714, 2005.
[53]
M. Hedhammar, T. Gräslund and S. Hober, "Protein engineering strategies for selective protein purification," Chemical Engineering & Technology, vol. 28, no. 11, pp. 1315-1325, 2005.
[54]
M. Linhult et al., "Improving the tolerance of a protein a analogue to repeated alkaline exposures using a bypass mutagenesis approach," Proteins : Structure, Function, and Bioinformatics, vol. 55, no. 2, pp. 407-416, 2004.
[55]
M. Hedhammar et al., "Negatively charged purification tags for selective anion-exchange recovery," Protein Engineering Design & Selection, vol. 17, no. 11, pp. 779-786, 2004.
[56]
M. Linhult et al., "Evaluation of different linker regions for multimerization and coupling chemistry for immobilization of a proteinaceous affinity ligand," Protein Engineering, vol. 16, no. 12, pp. 1147-1152, 2003.
[57]
T. Gräslund et al., "Integrated strategy for selective expanded bed ion-exchange adsorption and site-specific protein processing using gene fusion technology," Journal of Biotechnology, vol. 96, no. 1, pp. 93-102, 2002.
[58]
T. Gräslund et al., "Integrated strategy for selective expanded bed ion-exchange adsorption and site-specific protein processing using gene fusion technology," Journal of Biotechnology, vol. 96, no. 1, pp. 93-102, 2002.
[59]
T. Gräslund et al., "Strategy for highly selective ion-exchange capture using a charge-polarizing fusion partner," Journal of Chromatography A, vol. 942, no. 1-2, pp. 157-166, 2002.
[60]
S. Danielsen et al., "In vitro selection of enzymatically active lipase variants from phage libraries using a mechanism-based inhibitor," Gene, vol. 272, no. 02-jan, pp. 267-274, 2001.
[61]
T. Gräslund et al., "Charge engineering of a protein domain to allow efficient ion-exchange recovery," Protein Engineering, vol. 13, no. 10, pp. 703-709, 2000.
[62]
D. Legendre et al., "Display of active subtilisin 309 on phage : Analysis of parameters influencing the selection of subtilisin variants with changed substrate specificity from libraries using phosphonylating inhibitors," Journal of Molecular Biology, vol. 296, no. 1, pp. 87-102, 2000.
[63]
T. Gräslund et al., "Production of a Thermostable DNA Polymerase by Site-Specific Cleavage of a Heat-Eluted Affinity Fusion Protein," Protein Expression and Purification, vol. 9, pp. 125-132, 1997.
Icke refereegranskade
Artiklar
[64]
O. Thomas et al., "Epstein Barr Virus molecular mimicry to Anoctamin 2 : exploring dual T cell specificities," Multiple Sclerosis Journal, vol. 29, pp. 36-37, 2023.
[65]
A. Vorobyeva et al., "Evaluation of influence of albumin binding domain position on biodistribution of HER2-targeting DARPin-DM1 drug conjugates using radiolabeling," European Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. SUPPL 1, pp. S772-S773, 2023.
[66]
A. Vorobyeva et al., "Evaluation of influence of cytotoxic payload on biodistribution of HER2-targeting affibody-drug conjugates using a radioactive label," European Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. SUPPL 1, pp. S282-S282, 2022.
[67]
S. Rinne et al., "HER3-targeted drug delivery : Preclinical characterization of (HE)3-ZHER3-ABD-mcDM1 using Tc-99m," European Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. SUPPL 1, pp. S654-S655, 2022.
[68]
O. Thomas et al., "Investigating the T cell response to Anoctamin-2 and Epstein-Barr virus nuclear antigen 1 in multiple sclerosis using antigen-coupled beads," Multiple Sclerosis Journal, vol. 28, no. 3_SUPPL, pp. 234-235, 2022.
[69]
O. Thomas et al., "Re-visiting alpha beta-crystallin : EBNA1 antibody crossreactivity and CRYAB-specific T cell responses in multiple sclerosis," Multiple Sclerosis Journal, vol. 28, no. 3_SUPPL, pp. 233-234, 2022.
[70]
O. Thomas et al., "Comprehensive autoantigen panel to determine individual immune profiles in multiple sclerosis," Multiple Sclerosis Journal, vol. 27, no. 2_SUPPL, pp. 50-51, 2021.
[71]
T. Xu et al., "Imaging-guided co-targeting of HER2 and EpCAM using trastuzumab and DARPin-toxin fusion protein for theranostics of ovarian cancer," European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. SUPPL 1, pp. S69-S69, 2021.
[72]
A. Vorobyeva et al., "Selection of Optimal Radiolabel Position and Composition in DARPin Ec1 for High-Contrast Imaging of EpCAM Expression in Prostate Cancer," European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. SUPPL 1, pp. S19-S19, 2021.
[73]
M. Bronge et al., "T cell reactivity screening reveals four novel CNS autoantigens in multiple sclerosis," Multiple Sclerosis Journal, vol. 27, no. 2_SUPPL, pp. 344-345, 2021.
[74]
T. Xu et al., "Evaluation of Molecular Design of HER2-targeting Affibody-drug Conjugates for Drug Delivery to Ovarian Cancer," European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. SUPPL 1, pp. S10-S10, 2020.
[75]
M. Altai et al., "Evaluation Of Several Newly Designed Affibody-based Drug Conjugates Using Radionuclide-based Techniques : A Powerful Tool For Drug Development," European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. SUPPL 1, pp. S715-S716, 2019.
[76]
A. Vorobyeva et al., "Imaging of EpCAM expression in pancreatic cancer using radiolabelled DARPin Ec1," European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. SUPPL 1, pp. S749-S750, 2019.
[77]
M. Altai et al., "Improving of molecular design of a novel Affibody-fused HER2-recognising anticancer toxin using radionuclide-based techniques," European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, pp. S178-S178, 2016.
[78]
V. Tolmachev et al., "HEHEHE : a new chelator for [Tc-99m(CO)(3)](+)-labeling assembling His(6)-tag in protein purification," Nuclear Medicine and Biology, vol. 37, no. 6, pp. 698-698, 2010.
[79]
L. M. Orre et al., "FUNCTIONAL STUDIES OF S100A6 USING PROTEOMICS," Anticancer Research, vol. 28, no. 5C, pp. 3430-3431, 2008.
[80]
E. Lundberg et al., "Development of a platform for highthroughput quality assurance of monospecific polyclonal antibodies based on confocal scanning laser microscopy and FRET analysis," Molecular & Cellular Proteomics, vol. 5, no. 10, pp. S222-S222, 2006.
Övriga
[81]
W. Yin et al., "A comparison of affibody conjugates loaded with auristatin and maytansine derived drugs," (Manuscript).
[82]
J. Seijsing et al., "An engineered affibody molecule with pHdependent binding to FcRn mediates extended circulatory half-lifeof a fusion protein," (Manuscript).
[83]
[84]
M. Malm et al., "Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins," (Manuscript).
[85]
[86]
K. Larsson et al., "Novel antigen design for the generation of G-protein-coupled receptorantibodies.," (Manuscript).
[87]
H. Qin, T. Gräslund and H. Brismar, "Quantum dot-affibody fluorescence probes for single molecule tracking in living cell membranes," (Manuscript).
[88]
[89]
S. Grimm et al., "Selection and characterization of affibody molecules interfering with the interaction between Ras and Raf," (Manuscript).
[90]
J. Li et al., "Selection of affibody molecules blocking hormone-binding to the insulin-like growth factor 1 receptor," (Manuscript).
[91]
C. Hofström et al., "Step-wise down regulationof the epidermal growth factor receptor by affinity-based intracellular redirection," (Manuscript).
[92]
[93]
E. Elgstrand Wettergren et al., "Up-regulation of endogenous GAD67 expression in vivo using designed zinc finger-based transcription factors," (Manuscript).
Patent
Patent
[94]
[95]
Senaste synkning med DiVA:
2024-05-19 01:49:52